Compare Bristol-Myers Squibb Co (BMY) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Tesla, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.93 (market cap $129.94B), while Tesla, Inc. trades at $324.39 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 10.1× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| BMY | TSLA | |
|---|---|---|
Market Cap | $129.94B | $1.31T |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $489.88 |
52-Week Low | $42.60 | $298.16 |
Enterprise Value | $163.92B | $1.29T |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Tesla (TSLA) trades at $330.87, up 0.7% on the day, with a bearish technical signal from moving averages and a mixed fundamental picture. The stock shows high valuation multiples (P/E 308.16, P/S 11.36) amid declining profitability, with net income margin falling to 3.67% in 2025 from 15.49% in 2023. Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV model, but Q2 2026 earnings missed expectations.
Outlook remains polarized: analyst consensus price target of $393.87 suggests 19% upside, but high valuation and margin compression pose risks. Key catalysts include autonomy advancements and energy/robotics growth, while competition and execution challenges weigh on sentiment. The stock's trajectory hinges on delivering AI-driven revenue streams beyond automotive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
